https://www.barrons.com/articles/pfizer-merck-stock-pharma-prices-trump-dbab7d47
The order itself, however, looks like it could be a blessing in disguise for big pharma, fundamentally restructuring the U.S. drug industry in a way that hurts pharmacy-benefit managers.
Drugmakers have blamed
pharmacy-benefit managers for high drug prices in the U.S. The order appears designed to broaden the direct-to-consumer market, where
patients pay drugmakers cash for medicines without using normal drug channels.
分析表示藥價高企係藥局ge錯 而非製藥廠
因此好似CVS D pharmacy 就跌
製藥廠反而升



因爲預期會從塑整個藥品銷售行業